Terrie Curran, President and Chief Executive at Phathom Pharmaceuticals, Inc. (PHAT), sold 1,436 shares at $8.54 ($12K) on 2023-03-01, disclosed to the SEC on 2023-03-03.
Scheduled sale ($12k) by President and Chief Executive under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| PHAT | SELL | 2025-01-23 | $252K | — | Filing → |
| ARQT | SELL | 2024-11-13 | $189K | — | Filing → |
| PHAT | SELL | 2024-07-17 | $793K | — | Filing → |